Skip to main content
Contact Us
Subscribe
E-Edition
84°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by OKYO Pharma LTD
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
April 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
April 02, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
March 22, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
March 20, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
February 09, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
January 31, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
October 31, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
October 09, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
October 05, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 15, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Limited Announces Withdrawal of Public Offering
September 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Public Offering of Ordinary Shares
September 13, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
August 30, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
August 29, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
August 15, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Limited Announces Withdrawal of Public Offering
July 31, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
July 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
July 27, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
June 06, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
May 11, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
May 03, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
May 02, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Tickers
OKYO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.